EJNMMI Research · 2020 · 22 citations · 24 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingImage InterpretationMolecular ImagingOncologic Nuclear ImagingPositron Emission TomographyProstate CancerProstate Cancer ImagingProstate ImagingTumor Receptor ImagingInterobserver Agreement In StagingProstate Cancer DiagnosisProstate Computed TomographyProstate Disease ImagingProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen Positron Emission TomographyPsma-pet ImagingReporting Criteria
Abstract Background Prostate-specific membrane antigen (PSMA) ligand PET/CT has already provided promising results in prostate cancer (PC) imaging, yet simple and reproductible reporting criteria are still lacking. This study aimed at retrospectively evaluating interobserver agreement of [ 68 Ga]Ga-PSMA-11 PET/CT images interpretation according to PC molecular imaging standardized evaluation (PROMISE) criteria and reproducibility of PSMA reporting and data systems (RADS). Methods Forty-three patients with newly diagnosed, histologically proven intermediate- or high-risk PC, eligible for radical prostatectomy and who underwent [ 68 Ga]Ga-PSMA-11 PET/CT before surgery were retrospectively included. Three nuclear medicine physicians (2 experienced and 1 resident) independently reviewed PET/CT images. Interpretation of [ 68 Ga]Ga-PSMA-11 PET/CT images was based on PROMISE criteria including miTNM staging and lesions miPSMA expression score visual estimation and PSMA-RADS version 1.0 for a given scan. Readers’ agreement was measured using Krippendorff’s coefficients Results Agreement between observers was almost perfect (coefficient ≥ 0.81) for miM; it was substantial (coefficient ≥ 0.61) for the following criteria: miT, miN, PSMA-RADS, and miPSMA expression score of primary PC lesion and metastases. However, agreement was moderate (coefficient = 0.41–0.60) for miPSMA score of positive lymph nodes and for detection of PC primary lesion. Conclusion Visual interpretation of [ 68 Ga]Ga-PSMA-11 PET/CT images in patients with newly diagnosed PC in a clinical setting leads to at least substantial agreement for PROMISE criteria and PSMA-RADS classification except for PC primary lesion detection and for miPSMA expression scoring of positive lymph nodes that might have been hampered by the interindividual variability of reference organs PSMA expression.
24
Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations
Medicine, Nuclear Medicine, Oncology +14
Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
Wolfgang P. Fendler, Jérémie Calais, Matthias Eiber et al. · JAMA Oncology · 2019 · 787 citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Alberto Briganti, Alessandro Larcher, Firas Abdollah et al. · European Urology · 2011 · 787 citations